NASDAQ:SYNHSyneos Health Stock Price, Forecast & News

Syneos Health's stock was trading at $57.30 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SYNH shares have increased by 9.1% and is now trading at $62.51.
View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last year. There are currently 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Syneos Health.

Syneos Health is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for Syneos Health.

Syneos Health Inc (NASDAQ:SYNH) posted its earnings results on Thursday, August, 6th. The company reported $0.58 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.38 by $0.20. The company had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $1 billion. Syneos Health had a return on equity of 9.63% and a net margin of 4.10%. The firm's quarterly revenue was down 13.1% compared to the same quarter last year. During the same period in the prior year, the business posted $0.74 EPS.
View Syneos Health's earnings history.

Syneos Health issued an update on its FY20 earnings guidance on Thursday, August, 6th. The company provided EPS guidance of $3.16-3.38 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.00. The company issued revenue guidance of $4.47-4.57 billion, compared to the consensus revenue estimate of $4.45 billion.

11 analysts have issued 1 year target prices for Syneos Health's shares. Their forecasts range from $45.00 to $82.00. On average, they expect Syneos Health's stock price to reach $64.00 in the next twelve months. This suggests a possible upside of 2.4% from the stock's current price.
View analysts' price targets for Syneos Health.

Media stories about SYNH stock have trended very negative recently, InfoTrie reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Syneos Health earned a news sentiment score of -3.5 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near term.
View the latest news about Syneos Health.

Some companies that are related to Syneos Health include Incyte (INCY), EXACT Sciences (EXAS), PPD (PPD), Charles River Laboratories Intl. (CRL), Icon (ICLR), Exelixis (EXEL), PRA Health Sciences (PRAH), Medpace (MEDP), BTG (BTGGF), National Research (NRC), Precigen (PGEN), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL), Luna Innovations (LUNA) and Pieris Pharmaceuticals (PIRS).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Syneos Health investors own include NVIDIA (NVDA), Pfizer (PFE), Icon (ICLR), Netflix (NFLX), Square (SQ), AT&T (T), Advanced Micro Devices (AMD), Boeing (BA), Alibaba Group (BABA) and JD.Com (JD).

Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."

Syneos Health's stock is owned by a number of institutional and retail investors. Top institutional shareholders include GW&K Investment Management LLC (1.34%), Principal Financial Group Inc. (0.70%), Palisade Capital Management LLC NJ (0.58%), Peregrine Capital Management LLC (0.50%), Jennison Associates LLC (0.43%) and Victory Capital Management Inc. (0.42%). Company insiders that own Syneos Health stock include Alistair Macdonald, Jason M Meggs, John M Dineen, Jonathan Olefson, Michelle Keefe, Paul Colvin and Robert Parks.
View institutional ownership trends for Syneos Health.

SYNH stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Mutual of America Capital Management LLC, Kornitzer Capital Management Inc. KS, Peregrine Capital Management LLC, SG Americas Securities LLC, Hennessy Advisors Inc., First Quadrant L P CA, and Ameritas Investment Partners Inc.. Company insiders that have sold Syneos Health company stock in the last year include Alistair Macdonald, Michelle Keefe, and Robert Parks.
View insider buying and selling activity for Syneos Health.

SYNH stock was bought by a variety of institutional investors in the last quarter, including GW&K Investment Management LLC, Premier Asset Management LLC, Principal Financial Group Inc., UBS Group AG, Natixis Advisors L.P., State Board of Administration of Florida Retirement System, Envestnet Asset Management Inc., and Scotia Capital Inc.. Company insiders that have bought Syneos Health stock in the last two years include Jason M Meggs, John M Dineen, Jonathan Olefson, and Paul Colvin.
View insider buying and selling activity for Syneos Health.

Shares of SYNH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SYNH stock can currently be purchased for approximately $62.51.

Syneos Health has a market capitalization of $6.52 billion and generates $4.68 billion in revenue each year. The company earns $131.26 million in net income (profit) each year or $2.83 on an earnings per share basis. Syneos Health employs 24,000 workers across the globe.

The official website for Syneos Health is www.syneoshealth.com.

Syneos Health's mailing address is 1030 Sync Street, Morrisville NC, 27560. The company can be reached via phone at 919-876-9300 or via email at [email protected]